权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Tulane University COVID Antibody and Immunity Network (TUCAIN)

杜兰大学新冠病毒抗体和免疫网络 (TUCAIN)

基本信息

批准号：
10855027
负责人：
JAMES E Robinson
金额：
$ 279.23万
依托单位：
TULANE UNIVERSITY OF LOUISIANA
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-30 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10855027
关键词：
2019-nCoV Address Advanced Development Algorithms Antibodies Antibody Response Applied Research Big Data Blood Blood specimen COVID-19 COVID-19 patient COVID-19 survivors COVID-19 treatment Cellular Immunity Clinical Clinical Data Collection Data Data Set Development Diagnosis Disease Evolution Funding Goals Hospitalization Humoral Immunities Immune response Immunity Immunocompromised Host Immunologics Individual Infection Knowledge Longevity Louisiana Malignant Neoplasms Measures Medicine Memory Methods Mission Pathogenesis Pathogenicity Patient-Focused Outcomes Patients Persons Plasma Recurrence Reporting Research Risk SARS-CoV-2 immunity Serology test Serum Special Population Survivors Systems Biology Technology Therapeutic Time Universities Vaccines Viral Viral Hemorrhagic Fevers Virus biobank cell mediated immune response cohort convalescent plasma coronavirus disease data integration human pathogen improved insight longitudinal analysis mortality neutralizing antibody novel personalized medicine prevent programs public health emergency response screening therapeutic evaluation treatment strategy

项目摘要

Overall Summary The SARS-CoV-2 virus, the causative agent of COVID-19, has infected a reported 13,810,247 persons globally as of July 16, 2020 with a mortality rate of 4.2%. In the State of Louisiana, over 7.3% of the 86,411 COVID-19 cases involve people living with cancer. Theoretically, convalescent plasma contains protective antibodies that neutralizes virus and mitigates its pathogenic effects. Yet, there remains a large gap in our understanding of the mechanisms that drive humoral and cellular immune responses and how these responses correlate with disease course and protection as well as the durability of those responses. Furthermore, there is a need for serological assays that measure these responses accurately for serodiagnosis and as correlates of immunity and protection. Without this knowledge, the true efficacy of convalescent plasma as therapy for COVID-19 and our understanding of the humoral immune response to SARS-CoV-2, especially in immunocompromised patients, will remain unknown. The overall goal of the Tulane University Convalescent Antibody and Immunity Network (TUCAIN) is to characterize this response with respect to functionality and durability. We will achieve this goal by investigating the following broad specific aims: (1) Characterize the evolution, function and longevity of the humoral immune response to COVID-19. (2) Identify cell mediated immune responses that contribute to durable or short-lived humoral immunity to SARS CoV-2. (3) Correlate protective and potentially pathogenic immune responses to the clinical course of hospitalized COVID-19 patients. We will achieve these goals by studying a diverse cohort of COVID-19 survivors and minimally sick seroconverters, including a large cohort of patients with malignancies. Using serial blood collections, we will apply several immunological technologies to study the evolution and durability of the immune response over time. We will also correlate these responses to patient outcomes and disease pathogenesis using a “big data”, systems biology approach. An approach, such as the one we propose, will allow us to determine if COVID-19 survivors develop long-term, antibody-based protection and we can confirm if convalescent plasma has therapeutic potential. This research will allow us to identify new targets for medicines and vaccines, inform personalized treatment strategies such as those required by immunocompromised patients with cancer, and to provide novel immunological algorithms applicable to a wide range of human pathogens.

整体总结